Literature DB >> 3709033

Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin.

S Urien, E Albengres, J L Pinquier, J P Tillement.   

Abstract

Altered concentrations of serum proteins and nonesterified fatty acids (NEFAs) often accompany malignant diseases. Free fractions (fu) of apazone and warfarin were measured by equilibrium dialysis in serum samples obtained from 31 patients with cancer and 18 control subjects. Mean fu values of both drugs were significantly higher in the patient group. Multivariate analysis showed albumin, NEFA, and AAG for apazone and albumin, NEFA, and age for warfarin accounted for 60% and 63%, respectively, of interpatient variation in bound/free drug concentration ratios in the group of patients with cancer. The interactions of apazone and warfarin with AAG were further characterized; the more avid site had association constants of 4.5 X 10(5) and 2.3 X 10(5) L/mol, respectively. Finally, it is strongly suggested that when hypoalbuminemia is present and a drug binds to AAG with an affinity constant comparable to or higher than that to albumin, then fu will become dependent on the concentration of AAG.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709033     DOI: 10.1038/clpt.1986.119

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Differences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseases.

Authors:  J L Pinquier; S Urien; P Chaumet-Riffaud; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

2.  Effect of protein binding of daptomycin on MIC and antibacterial activity.

Authors:  B L Lee; M Sachdeva; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

Review 4.  Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy.

Authors:  K McCormack; K Brune
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

5.  Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein.

Authors:  S Urien; J Barré; C Morin; A Paccaly; G Montay; J P Tillement
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

6.  Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration.

Authors:  P Muret; P Humbert; S Makki; P Bechtel; S Urien; J P Tillement
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

7.  Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.

Authors:  S Y King; A M Agra; H S Shen; C L Chi; D B Adams; V E Currie; J R Bertino; H J Pieniaszek; C Y Quon
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

9.  On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography.

Authors:  Jeanethe Anguizola; Cong Bi; Michelle Koke; Abby Jackson; David S Hage
Journal:  Anal Bioanal Chem       Date:  2016-06-11       Impact factor: 4.142

10.  N-glycan microheterogeneity regulates interactions of plasma proteins.

Authors:  Di Wu; Weston B Struwe; David J Harvey; Michael A J Ferguson; Carol V Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-15       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.